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This article is part of a discussion meeting issue 'Providing sustainable catalytic solutions for a rapidly changing world'.
Introduction
Enzymes have now been used for more than a century for various applications in food, agriculture, polymer synthesis, organic synthesis of fine chemicals and flavours, and especially in the production of pharmaceutical intermediates [1] [2] [3] [4] [5] [6] . In addition to the use of single (isolated) enzymes, the combination of several enzymes in cascade reactions or in microbial strains subjected to metabolic engineering [7] [8] [9] [10] undergone a tremendous development over the past 10-15 years, which was summarized in a review in 2012 [11] . In that article, three waves of biocatalysis were defined. The first wave (which started over a century ago) simply used plant or animal tissue extracts or microbial strains, containing an enzyme activity of interest for a given synthetic reaction, with all the downsides of ill-defined biocatalysts, side-reactions, lack of stability etc. The second wave, emerging around the 1980s, took advantage of gene technology, which enabled the cloning and expression of the enzyme of interest in a suitable microbial host. Most importantly, researchers could subject the enzyme to site-directed mutagenesis to improve its properties. Several companies could then produce useful biocatalysts immobilized on suitable carriers on a large scale setting the stage for a broad range of industrialized processes. The third wave started with advanced protein engineering methods developed in the 1990s, such as DNA shuffling and error-prone polymerase chain reaction in combination with high-throughput screening methods, now commonly called 'directed evolution'. Since then, biocatalysis has profited immensely from developments in molecular biology, rapid and cheap genome sequencing, and especially bioinformatics and computer modelling. Hence, engineering a wild-type enzyme may now take only a few months instead of years. This quotation from our review clearly underlines what has been achieved: 'In the past, an enzyme-based process was designed around the limitations of the enzyme; today, the enzyme is engineered to fit the process specification' [11] .
But what will the fourth wave of biocatalysis be? The quotation 'It is difficult to predict, especially about the future' (credited to Niels Bohr [12] ) shows that picking some recent developments might not be the best basis to identify the forerunner of things to come. Although our review was published only five years ago, one can already observe various facets of new developments in the area of biocatalysis and closely related fields such as metabolic engineering. The intention of this contribution is to give an overview of the most important recent achievements and to elaborate how these could present indicators of the fourth wave of biocatalysis approaching.
Emerging enzyme classes and novel non-natural reactions
Every decade seems to have its top enzyme type intensively investigated by many research groups (as discussed at major conferences in the field such as GRC Biocatalysis, the Biotrans series, the Enzyme Engineering Conference or the Biocat series). In the 1980s, lipases and ketoreductases were most frequently applied, and in the 1990s also epoxide hydrolases, aldolases and nitrilases were used by organic chemists. In the 2000s, synthesis of chiral amines became of major interest and transaminases and monoamine oxidases became the new 'rising stars' for this purpose. Since 2010, a lot of research has been devoted to imine reductases [13, 14] too. For other enzyme classes, it turned out that certain highly desired transformations did not yet make it into the biocatalysts' portfolio. A currently emerging enzyme class in this context are carboxylic acid reductases [15, 16] to access aldehydes under mild conditions without over-reduction to the alcohol. Furthermore, a synthetically useful natural Diels-Alderase (the spirotetronate cyclase AbyU) has recently been described [17] . Another important trend is the use of S-adenosyl methionine-dependent methyltransferases [18] serving as interesting 'alkylation' agents. Here, one limitation is the recycling of the required cofactor, which is currently the focus of intense research [19] .
Thanks to the major achievements made in protein engineering, also a range of novel nonnatural reactions, potentially useful for organic synthesis, could be implemented into protein scaffolds [20] . Most recent examples are the creation of an artificial metalloenzyme containing Grubbs' Ru catalyst, which after directed evolution was able to catalyse olefin metathesis (figure 1a). Interestingly, the reaction can take place in the periplasm of Escherichia coli, where the protein was functionally expressed [21] . P450 monooxygenases are well known for their ability to catalyse stereoselective hydroxylations and epoxidations on non-activated C-H bonds using molecular oxygen [25] [26] [27] . The Arnold group has recently pioneered by mutating P450 BM3 (originating from Bacillus megaterium and being a natural fusion protein with its redox Figure 1 . Enzymes can be engineered to catalyse various non-natural reactions. (a) Based on Grubbs' Ru catalyst, the protein streptavidin expressed in the periplasm of E. coli could be engineered to enable an olefin metathesis reaction [21] . (b) An engineered P450-monoxygenase (named 'P411') catalyses stereoselective cyclopropanation instead of forming an epoxide from styrene [22] . (c) A cytochrome c enzyme from R. marinus was engineered to catalyse Si-C bond formation in E. coli whole cells [23] . (d) Exciting the cofactor NAD(P)H in a ketoreductase enzyme by blue light allows a radical-induced stereoselective dehalogenation [24] .
partner) in a way that it now catalyses stereoselective cyclopropanation [22, 28] (figure 1b) or aziridination [29] , instead of forming an epoxide from styrene or its derivatives. This substantially broadened the scope for applications in organic synthesis. Very recently, the same group engineered the first known enzyme able to form a Si-C bond using a cytochrome c enzyme from Rhodotermus marinus as scaffold. The reaction takes place in E. coli whole cells and up to 8210 total turnovers could be achieved, while the product had high optical purity (95%ee) [23, 30] (figure 1c). Hyster and co-workers published a new 'trick', where they could use a ketoreductase to hold the cofactor NAD(P)H tightly in place next to the active site. Upon excitation of the cofactor by blue light they could enable a completely new chemistry in an enzyme scaffold, radical-induced stereoselective dehalogenation (figure 1d) [24, 31] . Moreover, depending on the choice of (R)-or (S)-selective ketoreductases, the product of the reaction had a matching absolute configuration. These exciting examples demonstrate that we are not at all at the limit of what enzymes can catalyse and for sure many new biocatalysts will be discovered or designed to provide organic chemists with novel synthesis options.
Learning from sequences and structures
The search for new biocatalysts, but especially the identification of suitable genes to assemble pathways for metabolic engineering, has also seen an extraordinary boost by the huge number of sequences available from public databases. Not only sequences of entire genomes from various organisms, but especially the information available from environmental DNA samples including non-culturable organisms (metagenomes) provides us with a rich source of novel potentially useful enzymes. As an example of the 'information content' now accessible by next-generation sequencing technology, the Banfield group identified 8 complete and 789 draft genomes in a single metagenome library from an aquifer water sample [32] . More recently, their analysis enabled the creation of a substantially expanded 'tree of life' after surveying genomic data from more than 1000 uncultivated organisms [33] . Keeping in mind that annotation of the function of these sequences is very challenging and often wrong or misleading, in turn the demand for suitable bioinformatic tools to unlock the hidden function is one of the key challenges to meet. Tools like 3DM can assist in analysing enzyme superfamilies to identify the function of an enzyme, but also to guide protein engineering as shown for the α/β-hydrolase fold enzyme superfamily and pyridoxal phosphate-dependent enzymes [34] [35] [36] . Substantial progress has also been made in biomolecular simulation by quantum mechanics/molecular mechanics methods to study mechanisms or protein dynamics complementing the available tools for enzyme design [37] [38] [39] .
The huge gap between available protein sequences (greater than 100 million) and solved three-dimensional structures of proteins (approx. 100 000) represents a further bottleneck in the elucidation of enzyme function and prediction of suitable mutations. Fortunately, there is also progress here. For instance, the Baker group has developed rules [40] on how to predict protein folding. They could demonstrate for a range of protein sequences from five different fold classes that the predicted structure and the experimentally determined structure from NMR spectroscopy matched very closely. More recently, the Woolfson group studied miniproteins to simplify the protein-folding problem and they could engineer protein stability this way too [41] . Hence, it can be expected that in the near future reliable structure prediction of large and much more complex proteins will be possible, which will for sure substantially facilitate rational enzyme design [42] .
Metabolic engineering
An early example for the switch of a three-enzyme cascade process using isolated (immobilized) biocatalysts to a whole cell technology using E. coli expressing all required enzymes is the hydantoin process. Here, a chemically synthesized racemic hydantoin is first hydrolyzed by a hydantoinase to yield the corresponding carbamoyl derivative, which is subsequently cleaved by a carbamoylase to afford the desired optically pure amino acid. Incorporation of a hydantoin racemase established a dynamic kinetic resolution with theoretically 100% yield starting from the racemate. The hydantoin process has the further advantage that nature has provided us with Dor L-selective hydantoinases/carbamoylases with broad substrate specificity and hence access to either D-or L-amino acids, including non-proteinogenic ones, is possible [43, 44] .
Nowadays, very complex pathways have been established in common microbial hosts such as E. coli, Saccharomyces cerevisiae, Yarrowia lipolytica, and others. Impressive examples are the production of artemisinin [45] or more recently of the polymer precursor 1,4-butanediol, developed by the company Genomatica (USA). Here, the key to identify the most suitable pathway was a sophisticated computational analysis based on known chemistry and enzyme classes [46] . Another example for a potential bulk chemical production is a process for nylon-6 developed by DSM (The Netherlands) [47] . DuPont (USA) established the biosynthesis of the polyunsaturated fatty acid eicosapentaenoic acid (EPA) in Y. lipolytica, achieving more than 56% of EPA in the total lipid fraction. This biotechnological route is now an attractive alternative to the isolation of EPA from the diminishing resource of fish oil [48] . Despite these achievements, there are still many key challenges in the area of metabolic engineering. One unsolved bottleneck is functional expression of the genes encoding the enzymes or proteins of interest in the recombinant microbial host. Even with codon-adapted synthetic genes, one often struggles with low expression levels or even sole formation of inclusion bodies. Further issues are the regulation of gene expression, avoidance of protein degradation and the metabolic burden for the host organism, if several foreign proteins have to be produced. Further challenges are toxicity or degradation of intermediates and product secretion to reach high product titres required for an industrial process. This can in part be overcome by using cell lysates to run in vitro enzyme cascade reactions [7] [8] [9] [10] . Important areas are also flux analysis and metabolomics. Here, substantial progress has been made recently, taking advantage of sophisticated analytical tools to identify the key intermediates and their time-resolved concentrations [14] . One potential strategy for better metabolic pathways is to create minimal cells. The recent example from the Venter group for the design of a minimal bacterial genome can however be disillusioning: out of the 473 genes present in the 'minimal' genome, 149 genes could not be assigned to a specific function, yet they were absolutely required for cell viability [49] . In turn, this teaches us that we still do not sufficiently understand how even a simple microorganism functions and what it requires for life. In turn, this is a prerequisite for reliable planning and implementation of a novel metabolic route. 
Summary
The examples given in this contribution should demonstrate that biocatalysis is steadily moving forward. It is to be expected that in the future combinations of enzymes-whether in cascade reactions or via metabolic engineering-will become even more important or even the 'first choice' strategy. Discovery of novel enzymes and their engineering can already be considered mature especially fostered by further improvements in bioinformatic analyses tools and computer-guided design of desired enzymes. This is facilitated further by novel ultrahigh-throughput methods [50] to screen huge metagenome enzyme libraries using microfluidic tools [51] or chip technologies [52] . A better planning of enzymatic routes by retrosynthetic analyses [53] [54] [55] and more frequent direct integration of biocatalytic steps into organic synthesis routes would be a further highly desirable development [56] .
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